| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
110,820,000 |
| Market
Cap: |
1.27(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.58 - $25.88 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Precision Biosciences is a clinical stage gene editing company focused on improving life by developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its wholly owned proprietary ARCUS genome editing platform. Co. is simultaneously conducting a Phase 1/2a clinical trial evaluating PBCAR0191 as a potential first-in-class and a Phase 1 clinical trial evaluating PBCAR19B as, if approved, a potential CD19-targeting CAR T cell therapies in adult patients with relapsed or refractory, B-cell malignancies.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
90,000 |
189,021 |
| Total Buy Value |
$0 |
$0 |
$43,200 |
$170,792 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
5 |
| Total Shares Sold |
2,480 |
210,683 |
365,092 |
452,513 |
| Total Sell Value |
$25,523 |
$100,755 |
$167,195 |
$249,561 |
| Total People Sold |
4 |
4 |
4 |
4 |
| Total Sell Transactions |
5 |
9 |
12 |
17 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kane Matthew R. |
President and CEO |
• • – |
2021-01-26 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,515 |
1,863,708 |
|
- |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-01-25 |
4 |
AS |
$13.74 |
$133,209 |
D/D |
(9,695) |
1,842,193 |
|
-17% |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-01-25 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
1,851,888 |
|
- |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-01-22 |
4 |
AS |
$13.53 |
$138,250 |
D/D |
(10,218) |
1,830,374 |
|
-16% |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-01-22 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
1,840,592 |
|
- |
|
| Thomson David S. |
Chief Operating Officer |
• – – |
2021-01-21 |
4 |
AS |
$16.49 |
$164,900 |
D/D |
(10,000) |
109,243 |
|
-17% |
|
| Kelly John Alexander |
Interim CFOOfficer |
• – – |
2021-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,800 |
|
6% |
|
| Scimeca Dario |
General Counsel and Secretary |
• – – |
2020-08-31 |
4 |
A |
$4.79 |
$15,117 |
D/D |
3,156 |
5,228 |
|
- |
|
| Ansari Abid |
Chief Financial Officer |
• – – |
2020-06-15 |
4 |
OE |
$1.20 |
$10,540 |
D/D |
8,783 |
144,401 |
|
- |
|
| Ansari Abid |
Chief Financial Officer |
• – – |
2020-05-15 |
4 |
OE |
$1.18 |
$11,576 |
D/D |
9,661 |
135,618 |
|
- |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2020-04-14 |
4 |
OE |
$1.18 |
$5,183 |
D/D |
4,392 |
3,862,738 |
|
- |
|
| Scimeca Dario |
General Counsel and Secretary |
• – – |
2020-02-28 |
4 |
A |
$5.61 |
$11,624 |
D/D |
2,072 |
2,072 |
|
- |
|
| Ansari Abid |
Chief Financial Officer |
• – – |
2020-01-06 |
4 |
OE |
$1.18 |
$24,187 |
D/D |
20,200 |
123,845 |
|
- |
|
| Heery Christopher |
Chief Medical Officer |
• – – |
2019-12-19 |
4 |
B |
$12.08 |
$30,021 |
D/D |
2,485 |
2,485 |
2.74 |
- |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2019-09-10 |
4 |
OE |
$1.18 |
$15,548 |
D/D |
13,176 |
3,858,346 |
|
- |
|
| Thomson David S. |
Chief Development Officer |
• – – |
2019-06-10 |
4 |
OE |
$1.18 |
$138,193 |
D/D |
117,113 |
117,113 |
|
- |
|
| Ansari Abid |
Chief Financial Officer |
• – – |
2019-06-10 |
4 |
OE |
$1.18 |
$124,233 |
D/D |
103,645 |
103,645 |
|
- |
|
| Yao Tony Dung Ling |
Director |
– • – |
2019-04-03 |
4 |
B |
$15.42 |
$100,030 |
I/I |
6,487 |
158,003 |
2.1 |
- |
|
| Fmr Corp |
See Remark 1 |
– – – |
2019-04-01 |
4 |
B |
$16.00 |
$800,000 |
I/I |
50,000 |
3,738,248 |
0.01 |
- |
|
| Fmr Corp |
See Remark 1 |
– – – |
2019-04-01 |
4 |
A |
$0.00 |
$0 |
I/I |
3,688,248 |
3,688,248 |
|
- |
|
| Yao Tony Dung Ling |
Director |
– • – |
2019-04-01 |
4 |
A |
$0.00 |
$502,466 |
I/I |
155,966 |
4,450 |
|
- |
|
| Yao Tony Dung Ling |
Director |
– • – |
2019-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,450 |
4,450 |
|
- |
|
| Schinazi Raymond F |
Director |
– • – |
2019-04-01 |
4 |
A |
$0.00 |
$502,466 |
I/I |
93,048 |
93,048 |
|
- |
|
| Goodman Corey S |
10% Owner |
– – • |
2019-04-01 |
4 |
A |
$0.00 |
$0 |
I/I |
4,215,141 |
4,265,141 |
|
- |
|
| Goodman Corey S |
10% Owner |
– – • |
2019-04-01 |
4 |
B |
$16.00 |
$800,000 |
I/I |
50,000 |
50,000 |
1.5 |
- |
|
179 Records found
|
|
Page 7 of 8 |
|
|
0.86 (8.08%) 
